MedTrace Logo

Effects of Telemonitoring in Quality of Life Amongst Cancer Patients

NCT06086990 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2024-04-08

No results posted yet for this study

Summary

This interventional study aims to explore the potential of a smartphone app, Contigo, in enhancing the quality of life for patients with various cancers compared to standard care. The investigators will asses effects on quality of life, depressive symptoms, and appointment adherence.

Conditions

  • Cancer
  • Telemonitoring
  • Telemedicine
  • Symptoms and Signs
  • Quality of Life

Interventions

DEVICE

Contigo Application

Contigo, a smartphone app, focuses on two main goals: monitoring cancer patients for early signs of drug toxicity and offering educational content to empower them in managing clinical challenges linked to their diagnosis and treatment. Monitoring involves patients inputting experiences via oncology-related questionnaires, with weekly checks for chemotherapy toxicity using a validated questionnaire (PRO-CTCAE). Severe cases trigger alerts, while milder ones receive educational guidance. Data collected is shared with healthcare providers. Educational content, backed by scientific evidence and expert collaboration, covers cancer-specific topics and healthcare processes to enhance patients' self-awareness and self-care practices.

Sponsors & Collaborators

  • Centro para la Prevención y Control del Cáncer (CECAN), Santiago, Chile

    collaborator UNKNOWN

  • Universidad Nacional Andres Bello

    lead OTHER

Principal Investigators

  • Bruno Nervi, MD · Pontificia Universidad Catolica de Chile

  • Manuel Gonzalez, PhD · Pontificia Universidad Catolica de Chile

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-01
Primary Completion
2024-12-31
Completion
2025-03-31

Countries

  • Chile

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06086990 on ClinicalTrials.gov